Recent development of balloon-occluded retrograde transvenous obliteration

J Gastroenterol Hepatol. 2019 Mar;34(3):495-500. doi: 10.1111/jgh.14463. Epub 2018 Sep 17.

Abstract

Gastric varices (GVs) are a major complication of portal hypertension in patients with liver cirrhosis. The mortality rate associated with the bleeding from GVs is not low. Balloon-occluded retrograde transvenous obliteration (BRTO) was first introduced by Kanagawa et al. as a treatment for isolated GVs in 1994. It has been performed most frequently in Asia, especially in Japan. Ethanolamine oleate was the original sclerosant used in the therapy. Since the late 2000s, BRTO using sodium tetradecyl sulfate foam or polidocanol foam as a sclerosant has been performed in many countries other than Japan. Then, early in the 2010s, modified BRTO techniques including vascular plug-assisted retrograde transvenous obliteration and coil-assisted retrograde transvenous obliteration were developed as an alternative treatment for GVs. This article provides a historical overview of BRTO using various sclerosants and modified BRTO techniques, such as plug-assisted retrograde transvenous obliteration and coil-assisted retrograde transvenous obliteration.

Keywords: balloon-occluded retrograde transvenous obliteration; coil; ethanolamine oleate; polidocanol; sodium tetradecyl sulfate; vascular plug.

Publication types

  • Review

MeSH terms

  • Balloon Occlusion / methods*
  • Balloon Occlusion / trends
  • Esophageal and Gastric Varices / etiology
  • Esophageal and Gastric Varices / therapy*
  • Humans
  • Hypertension, Portal / complications
  • Liver Cirrhosis / complications
  • Oleic Acids / therapeutic use
  • Polidocanol / therapeutic use
  • Sclerosing Solutions / therapeutic use
  • Sodium Tetradecyl Sulfate / therapeutic use

Substances

  • Oleic Acids
  • Sclerosing Solutions
  • Polidocanol
  • Sodium Tetradecyl Sulfate
  • ethanolamine oleate